Back to news

Belite Bio Announces Extension of FDA Review Timeline for Tinlarebant NDA

Globe Newswire•20/11/2026•08:00 ET
0

Key Highlights

  • ➤FDA extends tinlarebant NDA review three months, setting May 12, 2027 PDUFA date
  • ➤FDA may communicate proposed labeling and postmarketing requests by April 12, 2027
  • ➤Tinlarebant’s Phase 3 DRAGON trial met its primary endpoint in STGD1

SAN DIEGO, Nov. 20, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio(®)” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that (i) it has extended the review period for the New Drug Application (NDA) for tinlarebant for the treatment of Stargardt disease type 1 (STGD1) by three months, with the extended Prescription Drug User Fee Act (PDUFA) action date being May 12, 2027, and (ii) if no major deficiencies are identified during FDA’s ongoing review, the FDA plans to communicate proposed labeling requests and any anticipated postmarketing requirement requests, if necessary, with the Company by April 12, 2027.

The extension provides the FDA with additional time to review information provided in support of the NDA. Belite Bio remains committed to working closely with FDA throughout the review process, and is confident in the clinical evidence supporting tinlarebant and its potential to address the significant unmet medical need in the STGD1 patient population.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in